Skip to main content

Table 2 All adverse events reported by frequency >5%

From: Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT

 

FPV/r 1400/100 mg + TDF/FTC QD N = 53

ATV/r 300/100 mg + TDF/FTC QD N = 53

Diarrhea

28 (53%)

13 (25%)

Blood bilirubin increased

0

16 (30%)

Nausea

8 (15%)

6 (11%)

Rash

9 (17%)

5 (9%)

Fatigue

6 (11%)

7 (13%)

Headache

5 (9%)

3 (6%)

Hyperbilirubinemia

0

8 (15%)

Cough

4 (8%)

3 (6%)

Nasopharyngitis

3 (6%)

4 (8%)

Upper respiratory tract infection

2 (4%)

4 (8%)

Arthralgia

0

5 (9%)

Insomnia

2 (4%)

3 (6%)

Ocular icterus

0

5 (9%)

Syphilis

5 (9%)

0

Depression

3 (6%)

1 (2%)

Herpes zoster

1 (2%)

3 (6%)

Dizziness

3 (6%)

0

Jaundice

0

3 (6%)

Paresthesia

3 (6%)

0